Clarithromycin resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Malaysia

J Dig Dis. 2010 Apr;11(2):101-5. doi: 10.1111/j.1751-2980.2010.00423.x.

Abstract

Objective: To determine the prevalence of primary clarithromycin resistance amongst Helicobacter pylori (H. pylori) strains in Malaysian patients with gastroduodenal diseases, by using restriction fragment length polymorphism (RFLP) in domain V of 23S rRNA.

Methods: Gastric biopsies were obtained from H. pylori positive patients undergoing gastroscopy. DNA extraction was followed by PCR amplification using the primers Hp23-1 and Hp23-2 flanking a region of 425bp within the bacterial 23S rRNA peptidyltranferase (Hp23S fragment). Analysis of the 23S rRNA gene mutations is based on the generation of restriction sites for two restriction enzymes: BbsI and BsaI, which correspond to the base substitutions characteristic of clarithromycin resistance from A to G at positions 2142 and 2143, respectively.

Results: Gastric biopsy samples were obtained from 107 patients. A fragment of size 425bp corresponding to that expected from amplification of domain V of 23S rRNA was PCR-amplified from only 105 samples. The amplicon was subsequently subjected to restriction by BbsI and BsaI. Only 1 sample (0.95%) had the BbsI mutation (base substitution at A2142G) and 2 samples (1.90%) the BsaI mutation (base substitution at A2143G). Thus 3 of 105 (2.9%) samples harbored clarithromycin resistant strains.

Conclusion: In our experience, PCR-RFLP is a rapid and precise method to detect the resistance of H. pylori to clarithromycin. Using this method, a low prevalence of clarithromycin resistance was detected in our local Malaysian strains. This augurs well for the continued use of clarithromycin as a first line drug in the treatment and eradication of H. pylori infection.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Biopsy
  • Clarithromycin / therapeutic use*
  • Drug Resistance, Bacterial / genetics*
  • Female
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / epidemiology
  • Helicobacter Infections / microbiology*
  • Helicobacter pylori / genetics*
  • Humans
  • Malaysia / epidemiology
  • Male
  • Middle Aged
  • Point Mutation / genetics*
  • Polymorphism, Restriction Fragment Length
  • Prevalence
  • RNA, Ribosomal, 23S / genetics*
  • Retrospective Studies
  • Stomach / microbiology
  • Stomach / pathology

Substances

  • Anti-Bacterial Agents
  • RNA, Ribosomal, 23S
  • Clarithromycin